BioNTech Accounts Payable vs Long Term Investments Analysis

BNTX Stock

USD 113.13 4.90 4.53%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Accounts Payable and its Long Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Accounts Payable vs Long Term Investments

Accounts Payable vs Long Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Accounts Payable account and Long Term Investments. At this time, the significance of the direction appears to have very strong relationship.

The correlation between BioNTech's Accounts Payable and Long Term Investments is 0.89. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Long Term Investments in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Accounts Payable and Long Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of BioNTech SE are associated (or correlated) with its Long Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Investments has no effect on the direction of Accounts Payable i.e., BioNTech's Accounts Payable and Long Term Investments go up and down completely randomly.

Correlation Coefficient

0.89

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents BioNTech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of BioNTech SE are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Long Term Investments

Long Term Investments is an item on the asset side of BioNTech balance sheet that represents investments BioNTech SE intends to hold for over a year. BioNTech SE long term investments may include different instruments such as stocks, bonds, real estate and cash.

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	5.4M	18.9M	7.9M	7.5M
Depreciation And Amortization	78.2M	121.1M	183.4M	192.6M

Interest Expense Depreciation And Amortization

BioNTech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.76	0.87	0.85	1.0	0.98	0.62	-0.93	0.99	0.94	0.94	0.88	0.74	0.94	0.69	0.82	0.64	0.76	0.62	0.87	0.64	0.86	0.75	0.97	1.0	0.14
Short Long Term Debt Total	0.76		0.86	0.88	0.73	0.77	0.76	-0.58	0.68	0.73	0.58	0.59	0.39	0.57	0.78	0.53	0.82	0.43	0.57	0.87	0.83	0.89	0.4	0.74	0.76	0.56
Other Current Liab	0.87	0.86		0.97	0.85	0.8	0.44	-0.77	0.82	0.71	0.76	0.56	0.33	0.69	0.87	0.46	0.66	0.36	0.47	0.97	0.69	0.96	0.35	0.76	0.89	0.2
Total Current Liabilities	0.85	0.88	0.97		0.82	0.78	0.46	-0.68	0.79	0.7	0.67	0.56	0.34	0.63	0.94	0.47	0.67	0.38	0.55	1.0	0.61	1.0	0.36	0.75	0.88	0.14
Total Stockholder Equity	1.0	0.73	0.85	0.82		0.98	0.62	-0.95	1.0	0.95	0.95	0.9	0.76	0.95	0.65	0.83	0.63	0.78	0.61	0.85	0.63	0.84	0.78	0.97	0.99	0.13
Property Plant And Equipment Net	0.98	0.77	0.8	0.78	0.98		0.75	-0.93	0.98	0.98	0.94	0.94	0.81	0.96	0.58	0.88	0.69	0.82	0.64	0.8	0.72	0.8	0.82	0.99	0.97	0.27
Current Deferred Revenue	0.62	0.76	0.44	0.46	0.62	0.75		-0.53	0.6	0.8	0.55	0.79	0.72	0.63	0.27	0.79	0.69	0.74	0.62	0.46	0.8	0.49	0.72	0.77	0.59	0.74
Net Debt	-0.93	-0.58	-0.77	-0.68	-0.95	-0.93	-0.53		-0.95	-0.88	-1.0	-0.86	-0.72	-0.98	-0.44	-0.78	-0.55	-0.72	-0.49	-0.71	-0.64	-0.69	-0.74	-0.91	-0.92	-0.13
Retained Earnings	0.99	0.68	0.82	0.79	1.0	0.98	0.6	-0.95		0.95	0.96	0.91	0.78	0.97	0.61	0.85	0.59	0.8	0.62	0.82	0.6	0.81	0.8	0.97	0.99	0.09
Accounts Payable	0.94	0.73	0.71	0.7	0.95	0.98	0.8	-0.88	0.95		0.9	0.98	0.88	0.94	0.5	0.94	0.68	0.9	0.7	0.73	0.68	0.73	0.89	0.99	0.92	0.28
Cash	0.94	0.58	0.76	0.67	0.95	0.94	0.55	-1.0	0.96	0.9		0.87	0.74	0.98	0.44	0.8	0.55	0.75	0.49	0.71	0.64	0.68	0.76	0.92	0.93	0.14
Non Current Assets Total	0.88	0.59	0.56	0.56	0.9	0.94	0.79	-0.86	0.91	0.98	0.87		0.96	0.94	0.33	0.99	0.57	0.97	0.7	0.6	0.6	0.59	0.97	0.96	0.85	0.24
Non Currrent Assets Other	0.74	0.39	0.33	0.34	0.76	0.81	0.72	-0.72	0.78	0.88	0.74	0.96		0.85	0.13	0.99	0.39	1.0	0.7	0.39	0.42	0.39	1.0	0.86	0.69	0.14
Cash And Short Term Investments	0.94	0.57	0.69	0.63	0.95	0.96	0.63	-0.98	0.97	0.94	0.98	0.94	0.85		0.39	0.89	0.55	0.85	0.58	0.67	0.62	0.65	0.86	0.96	0.92	0.15
Net Receivables	0.69	0.78	0.87	0.94	0.65	0.58	0.27	-0.44	0.61	0.5	0.44	0.33	0.13	0.39		0.25	0.52	0.17	0.37	0.91	0.38	0.92	0.15	0.55	0.72	0.0
Good Will	0.82	0.53	0.46	0.47	0.83	0.88	0.79	-0.78	0.85	0.94	0.8	0.99	0.99	0.89	0.25		0.49	0.99	0.73	0.51	0.54	0.51	0.99	0.92	0.78	0.24
Common Stock Total Equity	0.64	0.82	0.66	0.67	0.63	0.69	0.69	-0.55	0.59	0.68	0.55	0.57	0.39	0.55	0.52	0.49		0.42	0.35	0.66	0.7	0.67	0.4	0.67	0.63	0.44
Short Term Investments	0.76	0.43	0.36	0.38	0.78	0.82	0.74	-0.72	0.8	0.9	0.75	0.97	1.0	0.85	0.17	0.99	0.42		0.72	0.43	0.43	0.43	1.0	0.87	0.71	0.16
Non Current Liabilities Total	0.62	0.57	0.47	0.55	0.61	0.64	0.62	-0.49	0.62	0.7	0.49	0.7	0.7	0.58	0.37	0.73	0.35	0.72		0.6	0.52	0.61	0.7	0.68	0.6	0.23
Inventory	0.87	0.87	0.97	1.0	0.85	0.8	0.46	-0.71	0.82	0.73	0.71	0.6	0.39	0.67	0.91	0.51	0.66	0.43	0.6		0.61	1.0	0.41	0.77	0.9	0.12
Other Current Assets	0.64	0.83	0.69	0.61	0.63	0.72	0.8	-0.64	0.6	0.68	0.64	0.6	0.42	0.62	0.38	0.54	0.7	0.43	0.52	0.61		0.62	0.43	0.68	0.63	0.8
Total Liab	0.86	0.89	0.96	1.0	0.84	0.8	0.49	-0.69	0.81	0.73	0.68	0.59	0.39	0.65	0.92	0.51	0.67	0.43	0.61	1.0	0.62		0.41	0.77	0.89	0.15
Long Term Investments	0.75	0.4	0.35	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97	1.0	0.86	0.15	0.99	0.4	1.0	0.7	0.41	0.43	0.41		0.87	0.71	0.14
Property Plant And Equipment Gross	0.97	0.74	0.76	0.75	0.97	0.99	0.77	-0.91	0.97	0.99	0.92	0.96	0.86	0.96	0.55	0.92	0.67	0.87	0.68	0.77	0.68	0.77	0.87		0.95	0.25
Total Current Assets	1.0	0.76	0.89	0.88	0.99	0.97	0.59	-0.92	0.99	0.92	0.93	0.85	0.69	0.92	0.72	0.78	0.63	0.71	0.6	0.9	0.63	0.89	0.71	0.95		0.12
Non Current Liabilities Other	0.14	0.56	0.2	0.14	0.13	0.27	0.74	-0.13	0.09	0.28	0.14	0.24	0.14	0.15	0.0	0.24	0.44	0.16	0.23	0.12	0.8	0.15	0.14	0.25	0.12

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Short Long Term Debt Total	76.5M	240.2M	301.5M	212.2M	219.1M	162.4M
Other Current Liab	16.4M	487.6M	1.6B	2.1B	1.1B	744.1M
Total Current Liabilities	138.1M	606.0M	3.5B	3.0B	2.1B	1.3B
Total Stockholder Equity	493.5M	1.4B	11.9B	20.1B	20.2B	21.3B
Other Liab	205.6M	97.1M	109.7M	283.9M	326.5M	166.9M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Property Plant And Equipment Net	148.1M	326.0M	520.4M	821.1M	971.6M	1.0B
Current Deferred Revenue	93.6M	391.5M	189.1M	77.1M	353.3M	371.0M
Net Debt	(450.2M)	(970.0M)	(1.4B)	(13.7B)	(11.4B)	(10.9B)
Retained Earnings	(424.8M)	(409.6M)	9.9B	18.8B	19.8B	20.8B
Accounts Payable	20.5M	102.3M	160M	204.1M	354M	371.7M
Cash	519.1M	1.2B	1.7B	13.9B	11.7B	12.2B
Non Current Assets Total	237.5M	651.7M	758.5M	1.4B	3.5B	3.7B
Non Currrent Assets Other	2K	1.0M	800K	6.5M	187.1M	196.5M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Long Term Debt	68.9M	231.0M	171.6M	176.2M	191M	116.1M
Cash And Short Term Investments	520.8M	1.3B	2.1B	14.1B	16.5B	17.4B
Net Receivables	20.2M	166.4M	12.4B	7.1B	2.3B	3.0B
Good Will	3.0M	53.7M	57.8M	61.2M	362.5M	380.6M
Common Stock Total Equity	166.8M	193.3M	232.3M	246.3M	283.3M	185.2M
Common Stock Shares Outstanding	211.5M	248.5M	259.7M	249.8M	242.7M	229.1M
Short Term Investments	1.7M	137.2M	381.6M	189.4M	4.9B	5.1B
Liabilities And Stockholders Equity	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Non Current Liabilities Total	166.0M	340.8M	455.5M	272.9M	689.9M	378.2M
Inventory	11.7M	64.1M	502.5M	439.6M	357.7M	190.9M
Other Current Assets	1.2M	392.6M	113.8M	272.3M	280.9M	146.4M
Other Stockholder Equity	(5.5M)	1.8B	(3.8M)	(5.3M)	(10.8M)	(10.3M)
Total Liab	304.2M	946.8M	3.9B	3.2B	2.8B	1.7B
Property Plant And Equipment Gross	148.1M	326.0M	594.6M	821.1M	1.2B	1.2B
Total Current Assets	560.2M	1.7B	15.1B	21.9B	19.5B	20.5B
Accumulated Other Comprehensive Income	691.5M	25.5M	1.8B	979.3M	244.8M	232.6M
Short Term Debt	7.6M	15.2M	129.9M	36M	56.2M	37.6M
Intangible Assets	86.5M	109.8M	144.6M	158.5M	781.7M	820.8M
Common Stock	232.3M	246.3M	246.3M	248.6M	285.9M	218.0M
Property Plant Equipment	116.0M	148.1M	326.0M	520.4M	598.5M	628.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Accounts Payable vs Long Term Investments Analysis

Accounts Payable vs Long Term Investments

Accounts Payable vs Long Term Investments Correlation Analysis

Correlation Coefficient

Accounts Payable

Long Term Investments

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Also Currently Popular

Additional Tools for BioNTech Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Inventory	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Retained Earnings	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Non Currrent Assets Other

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Retained Earnings	- 0.95	Net Debt
Net Debt	- 0.95	Total Stockholder Equity
Net Debt	- 0.93	Property Plant And Equipment Net
Net Debt	- 0.93	Total Assets